Where to buy ibrutinib/ibrutinib

Ibrutinib/Ibrutinib is an irreversible Bruton's tyrosine kinase (BTK) inhibitor that was approved by the U.S. Food and Drug Administration (FDA) in 2013 as a new therapy for the treatment of B-cell malignancies. As a first-in-class drug, ibrutinib inhibits B cell receptor signaling by covalently binding to cysteine u200bu200b481 residue within the adenosine triphosphate binding site of BTK, an enzyme that plays an important role in cell proliferation and survival in B cell malignancies.

Ibrutinib is an oral, potent, selective and irreversibleBtk small molecule inhibitor. 14 It forms a covalent bond with the cysteine u200bu200bresidue (CYS-481) in the active site of Btk, thereby inhibiting Btk enzyme activity. 10 Ibrutinib also abolishes complete activation of Btk by inhibiting its autophosphorylation at Tyr-223. This inhibition prevents downstream activation of the BCR pathway, thereby blocking the growth, proliferation, and survival of malignant B cells. Ibrutinib was well tolerated and showed excellent efficacy in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, marginal zone lymphoma, and Wadenstrom's macroglobulinemia.

The original drug of ibrutinib has also been launched in China and has entered the scope of Class B medical insurance reimbursement. Patients who meet the indications can use medical insurance to purchase it. Ibrutinib is a prescription drug. In domestic hospitals or pharmacies, patients can purchase the drug based on the doctor's prescription information and cannot choose blindly. Ibrutinib original drugs or generic drugs are also sold overseas. The ingredients of these drugs are basically the same, and there may be differences in price. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.